Featured Research

from universities, journals, and other organizations

A More Reliable Test For Latent TB

Date:
March 15, 2007
Source:
American Thoracic Society
Summary:
Two new interferon-gamma blood test assays to detect latent tuberculosis infection (LTBI) showed customers were exposed to a supermarket employee in Holland who had smear-positive tuberculosis, while traditional tuberculin skin tests (TST) did not, according to a large contact study.

Two new interferon-gamma blood test assays to detect latent tuberculosis infection (LTBI) showed customers were exposed to a supermarket employee in Holland who had smear-positive tuberculosis, while traditional tuberculin skin tests (TST) did not, according to a large contact study.

Ailko Bossink, M.D., Ph.D., of the Department of Pulmonology at Diakonessenhuis Utrecht in The Netherlands, and eight associates recruited 785 supermarket customers who had not received BCG vaccine against tuberculosis, the immunizing agent prepared from Calmette-Guιren bacillus. TST results are not accurate in those vaccinated with BCG.

All individuals in the study cohort were recruited from over 20,000 customers who had shopped at the supermarket for more than 10 months. Many had numerous contacts with the infected employee, who had been contagious since February 2004. The large-scale contact investigation began in January 2005.

"One-third of the world's population is believed to harbor latent TB infection, or LTBI," said Dr. Bossink. "Approximately 5 to 15 percent of immunocompetent persons with LTBI will develop TB disease. In countries with a low-incidence of TB, the tracing and targeted treatment of individuals with LTBI constitutes the major pillar of TB control. "

For the study, researchers selected 469 customers randomly on the day that their TST was administered and 316 with a TST result of more than 0 mm.

TSTs are based on a skin reaction to injection, scratching or puncturing the skin with a purified protein derivative of tuberculosis bacterium. Swelling and redness indicate a positive result.

In the new blood tests, two interferon-gamma release assays (IGRAs) measure response to an antigen highly specific for Mycobacterium tuberculosis. One of the blood tests, QuantiFERON-TB Gold, has received approval from the U.S. Food and Drug Administration for use in the United States. The other has been approved for use in Europe.

"Among the 785 study participants, TST results were associated with age, whereas positive interferon-gamma blood test assay results were significantly associated with cumulative shopping time," said Dr. Bossink. "TST results were not associated with any measure of exposure to the index case in the supermarket."

The researchers noted that positive TST responses largely reflected delayed type hypersensitivity due to remote infection with M. tuberculosis acquired before the source case at the supermarket became infectious.Among the 759 shoppers who had valid results from both interferon-gamma blood assay, slightly over 80 percent (608) were concordant negative with both blood tests, while 72 were concordant positive and 79 were discordant. Overall agreement between the two tests was 89.6 percent.

"Although the interferon-gamma blood tests are now considered more specific and show a better correlation with exposure than TST, it has not been demonstrated whether they provide a valid basis for therapeutic decisions regarding treatment," said Dr. Bossink. "The risk of TB disease in the presence of a positive test result had not been established."

"Notably, positive interferon-gamma blood assays were observed in a significant proportion of recently exposed contacts with a negative TST result," he added. "The clinical significance of this finding merits further study if the blood tests are to replace the TST and be used for therapeutic decisions."

In an editorial on the research in the same issue of the journal, Madhukar Pai, M.D., Ph.D., and Dick Menzies, M.D., M.Sc., of McGill University in Montreal, Canada, wrote:

"The key question is whether the two new IGRAs are better than the TST in predicting the development of TB disease, and thus identifying persons who will benefit most from latent TB infection (LTBI) therapy. There is abundant evidence, from numerous large-scale cohorts and randomized trials, regarding the prognosis of untreated persons with positive TST results; this remains the greatest advantage of the TST."

"What is urgently needed is similar longitudinal studies of cohorts who have been tested with IGRA (ideally both IGRAs) and the TST," they continued. "However, in almost all low-incidence, high-income countries, it would be ethically impossible not to treat persons with evidence of LTBI. Moreover, in high-incidence countries, where treatment of LTBI is not the current standard of care, it would seem unethical to test for a condition without plans to offer appropriate treatment."

"However, this should not be a problem. Almost everyone would agree that individuals with concordant positive TST and IGRA are likely to have LTBI and they will never inform the question as to which test predicts active TB better. Thus, such patients can and should be managed appropriately. However, individuals with discordant results (TST+/IGRA- or vice versa) will be informative regarding the risk of development of active disease without treatment. In addition, because the clinical interpretation, and therefore management is unclear for persons with such discordant results, equipoise exists. Therefore, close observation without treatment is reasonable and ethical."

Reference:  Second issue for March 2007 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.



Story Source:

The above story is based on materials provided by American Thoracic Society. Note: Materials may be edited for content and length.


Cite This Page:

American Thoracic Society. "A More Reliable Test For Latent TB." ScienceDaily. ScienceDaily, 15 March 2007. <www.sciencedaily.com/releases/2007/03/070315075814.htm>.
American Thoracic Society. (2007, March 15). A More Reliable Test For Latent TB. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2007/03/070315075814.htm
American Thoracic Society. "A More Reliable Test For Latent TB." ScienceDaily. www.sciencedaily.com/releases/2007/03/070315075814.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins